PDCD1 and female reproductive organ cancer: PD-1/PD-L1 inhibitors such as pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab have presented anti-cancer effects on gynecological cancers and cancers originating from other organs [21,52,59,67].